Clinical sources

The evidence guiding our program and clinical assessment.

Everton's protocols follow the published guidelines of the major professional societies in each area of care. These are the primary sources our clinicians work from.

Weight & GLP-1 therapy

AACE — Algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease (2025 update)

American Diabetes Association — Standards of Care (obesity & weight management)

FDA prescribing information for GLP-1 receptor agonists

GLP-1 therapy — peer-reviewed evidence

STEP 1 — Once-weekly semaglutide in adults with overweight or obesity (New England Journal of Medicine, 2021)

SURMOUNT-1 — Tirzepatide once weekly for the treatment of obesity (New England Journal of Medicine, 2022)

SELECT — Semaglutide and cardiovascular outcomes in obesity without diabetes (New England Journal of Medicine, 2023)

STEP UP — Once-weekly semaglutide 7.2 mg in adults with obesity (The Lancet Diabetes & Endocrinology, 2025)

Efficacy of GLP-1 receptor agonists on weight, BMI, and waist circumference — meta-analysis of 47 randomized trials (Diabetes Care, 2025)

Cardiovascular risk reduction with GLP-1 receptor agonists — review (Circulation, 2026)

Cardiovascular outcomes of GLP-1-based medicines in overweight and obesity — umbrella review of meta-analyses (Obesity Reviews, 2026)

Metabolic health

American Diabetes Association — Standards of Care in Diabetes

American Heart Association — cardiometabolic risk and lipid management guidance

Endocrine Society — clinical practice guidelines

Hormone health

The Menopause Society — hormone therapy position statement

Endocrine Society — menopause and hormone therapy guidelines

ACOG — clinical guidance on menopause and midlife health

Hormone health — peer-reviewed evidence

The 2022 hormone therapy position statement of The North American Menopause Society (Menopause, 2022)

The Women's Health Initiative randomized trials and clinical practice — a review (JAMA, 2024)

Supplement interactions and contraindications

NIH Office of Dietary Supplements — fact sheets for health professionals, including each ingredient's interactions with medications

NCCIH — herb-drug interactions

LiverTox (NIDDK) — liver injury from medications, herbals, and dietary supplements

FDA — questions and answers on dietary supplements

MedlinePlus — herbs and supplements, with interaction and precaution detail

Guidelines evolve; our protocols are reviewed against current publications on a recurring basis. The trials cited here report average results in the populations studied — they are published research, not a prediction of any individual's results. This page is informational and is not medical advice.